214 related articles for article (PubMed ID: 15861037)
21. A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Takahama H; Asanuma H; Sanada S; Fujita M; Sasaki H; Wakeno M; Kim J; Asakura M; Takashima S; Minamino T; Komamura K; Sugimachi M; Kitakaze M
Basic Res Cardiol; 2010 Nov; 105(6):787-94. PubMed ID: 20852875
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Takayanagi R; Fujito K; Kimura K; Yamada Y
Biol Pharm Bull; 2017; 40(6):837-843. PubMed ID: 28566627
[TBL] [Abstract][Full Text] [Related]
23. Carvedilol: the new role of beta blockers in congestive heart failure.
Vanderhoff BT; Ruppel HM; Amsterdam PB
Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960
[TBL] [Abstract][Full Text] [Related]
24. Effects of beta-blockers on ventilation efficiency in heart failure.
Agostoni P; Apostolo A; Cattadori G; Salvioni E; Berna G; Antonioli L; Vignati C; Schina M; Sciomer S; Bussotti M; Palermo P; Fiorentini C; Contini M
Am Heart J; 2010 Jun; 159(6):1067-73. PubMed ID: 20569721
[TBL] [Abstract][Full Text] [Related]
25. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
26. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.
Fung JW; Chan SK; Yeung LY; Sanderson JE
Eur J Heart Fail; 2002 Aug; 4(4):489-94. PubMed ID: 12167389
[TBL] [Abstract][Full Text] [Related]
27. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
28. Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan.
Hu H; Jui HY; Hu FC; Chen YH; Lai LP; Lee CM
J Formos Med Assoc; 2007 Aug; 106(8):641-8. PubMed ID: 17711797
[TBL] [Abstract][Full Text] [Related]
29. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
30. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST).
Eichhorn EJ; Grayburn PA; Mayer SA; St John Sutton M; Appleton C; Plehn J; Oh J; Greenberg B; DeMaria A; Frantz R; Krause-Steinrauf H
Circulation; 2003 Nov; 108(19):2336-41. PubMed ID: 14597587
[TBL] [Abstract][Full Text] [Related]
31. Carvedilol in the treatment of chronic heart failure.
Moe G
Expert Opin Pharmacother; 2001 May; 2(5):831-43. PubMed ID: 11336626
[TBL] [Abstract][Full Text] [Related]
32. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.
Sanderson JE; Chan SK; Yip G; Yeung LY; Chan KW; Raymond K; Woo KS
J Am Coll Cardiol; 1999 Nov; 34(5):1522-8. PubMed ID: 10551702
[TBL] [Abstract][Full Text] [Related]
33. Beta-blocker pharmacogenetics in heart failure.
Shin J; Johnson JA
Heart Fail Rev; 2010 May; 15(3):187-96. PubMed ID: 18437562
[TBL] [Abstract][Full Text] [Related]
34. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
[TBL] [Abstract][Full Text] [Related]
35. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.
Pereira SB; Velloso MW; Chermont S; Quintão MM; Nunes Abdhala R; Giro C; Oliveira E Alves T; Camacho V; De Fátima Maia Contarato L; Pena FM; Balieiro HM; Garcia ML; Da Nóbrega AC; Ribeiro GS; Mesquita ET
Mol Med Rep; 2013 Jan; 7(1):259-65. PubMed ID: 23064657
[TBL] [Abstract][Full Text] [Related]
36. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
[TBL] [Abstract][Full Text] [Related]
37. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
[TBL] [Abstract][Full Text] [Related]
38. The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure.
Witte KK; Thackray S; Nikitin NP; Cleland JG; Clark AL
Eur J Heart Fail; 2005 Jun; 7(4):612-7. PubMed ID: 15921802
[TBL] [Abstract][Full Text] [Related]
39. Replacement of carvedilol for propranolol in patients with heart failure.
Marques F; Castro RB; Nobre F; Pintya AO; Gallo L; Maciel BC; Simões MV
Arq Bras Cardiol; 2010 Jul; 95(1):107-14. PubMed ID: 20563524
[TBL] [Abstract][Full Text] [Related]
40. Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure.
Palazzuoli A; Quatrini I; Vecchiato L; Scali C; De Paola V; Iovine F; Martini G; Nuti R
Minerva Cardioangiol; 2005 Aug; 53(4):321-8. PubMed ID: 16177676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
